^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CD19-CD34t metabolically programmed CAR transduced T-cells

i
Other names: CD19-CD34t metabolically programmed CAR transduced T-cells
Associations
Company:
Medical University of South Carolina
Drug class:
CD19-targeted CAR-T immunotherapy
Related drugs:
Associations
12ms
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
P1/2, N=27, Recruiting, Medical University of South Carolina | Not yet recruiting --> Recruiting | Phase classification: P1b --> P1/2
Enrollment open • Phase classification • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
over1year
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (clinicaltrials.gov)
P1b, N=27, Not yet recruiting, Medical University of South Carolina | Trial completion date: Feb 2026 --> Dec 2026 | Initiation date: Apr 2023 --> Aug 2023 | Trial primary completion date: Feb 2025 --> Aug 2025
Trial completion date • Trial initiation date • Trial primary completion date • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells
almost2years
New P1 trial • CAR T-Cell Therapy
|
BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 expression • BCL6 rearrangement • BCL2 rearrangement
|
cyclophosphamide • fludarabine IV • CD19-CD34t metabolically programmed CAR transduced T-cells